ATE556717T1 - Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus - Google Patents

Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus

Info

Publication number
ATE556717T1
ATE556717T1 AT10151641T AT10151641T ATE556717T1 AT E556717 T1 ATE556717 T1 AT E556717T1 AT 10151641 T AT10151641 T AT 10151641T AT 10151641 T AT10151641 T AT 10151641T AT E556717 T1 ATE556717 T1 AT E556717T1
Authority
AT
Austria
Prior art keywords
sars
cov
acute respiratory
respiratory syndrome
severe acute
Prior art date
Application number
AT10151641T
Other languages
English (en)
Inventor
Shibo Jiang
Yuxian He
Original Assignee
New York Blood Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc filed Critical New York Blood Ct Inc
Application granted granted Critical
Publication of ATE556717T1 publication Critical patent/ATE556717T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT10151641T 2005-02-08 2006-02-08 Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus ATE556717T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65104605P 2005-02-08 2005-02-08
US14192505A 2005-05-31 2005-05-31

Publications (1)

Publication Number Publication Date
ATE556717T1 true ATE556717T1 (de) 2012-05-15

Family

ID=36793717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10151641T ATE556717T1 (de) 2005-02-08 2006-02-08 Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus

Country Status (10)

Country Link
EP (1) EP1855719A4 (de)
JP (1) JP2008529504A (de)
AT (1) ATE556717T1 (de)
AU (1) AU2006213775C1 (de)
BR (1) BRPI0606148A2 (de)
CA (1) CA2595780A1 (de)
ES (1) ES2384497T3 (de)
MX (1) MX2007009512A (de)
NZ (1) NZ560328A (de)
WO (1) WO2006086561A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3155004T3 (da) * 2014-06-12 2021-04-06 Univ Do Porto Reitoria Vaccine til immunkompromitterede værter
EP4100055A2 (de) * 2020-02-06 2022-12-14 Vib Vzw Coronavirus-bindemittel
TWI818236B (zh) * 2020-02-19 2023-10-11 美商聯合生物醫學公司 用於檢測、預防和治療新型冠狀病毒(covid-19)疾病的設計胜肽及蛋白質
CN113292650B (zh) * 2020-02-24 2022-08-12 中国科学院微生物研究所 新型冠状病毒的人源单克隆抗体及其应用
CN113292649B (zh) * 2020-02-24 2022-08-12 中国科学院微生物研究所 新型冠状病毒的人源单克隆抗体及其应用
MX2022011142A (es) * 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
CN119438581A (zh) * 2020-03-13 2025-02-14 科美诊断技术股份有限公司 一种用于检测新型冠状病毒中和抗体的试剂盒
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测
WO2021202893A1 (en) * 2020-04-03 2021-10-07 Nonigenex, Inc. Detecting adaptive immunity to coronavirus
WO2021221137A1 (ja) * 2020-05-01 2021-11-04 花王株式会社 抗ＳＡＲＳ－ＣｏＶ－２抗体を用いた医薬品及び検査キット
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN111995675B (zh) * 2020-05-15 2021-03-23 潍坊医学院 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用
WO2021238910A1 (en) * 2020-05-25 2021-12-02 Guo Bingshi Anti-coronavirus spike protein antibodies and uses thereof
CN112017782A (zh) * 2020-06-01 2020-12-01 北京松果天目健康管理有限公司 SARS-CoV-2易感性的检测方法及新冠病毒重症风险预测方法
CA3179834A1 (en) * 2020-06-25 2021-12-30 David S. Block Ace2-fc fusion proteins and methods of use
WO2022015069A1 (ko) 2020-07-16 2022-01-20 (주)케어젠 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드
CN113945714B (zh) * 2020-07-16 2023-01-31 南京蓬勃生物科技有限公司 新型冠状病毒中和抗体类药物中和能力的检测方法
CN112010984B (zh) * 2020-08-04 2021-10-12 广州千扬生物医药技术有限公司 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白多聚体纳米疫苗
JP7773154B2 (ja) 2020-08-26 2025-11-19 国立大学法人 熊本大学 コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片
CN114181301B (zh) * 2020-09-14 2023-04-28 复旦大学 针对SARS-CoV-2的无ADE效应的中和抗体
CN113156129B (zh) * 2021-01-13 2022-04-05 广东菲鹏生物有限公司 中和抗体高敏检测方法及产品
CN115427441B (zh) * 2021-01-27 2023-09-05 保诺生物科技(江苏)有限公司 针对sars-cov-2的抗体
CN115109150B (zh) * 2021-01-31 2024-06-25 中南大学湘雅医院 新型冠状病毒单克隆抗体xy10及其应用
CN116973566A (zh) * 2021-02-03 2023-10-31 广东菲鹏生物有限公司 一种鉴别结合突变型抗原的抗体的方法及试剂
EP4089112A1 (de) * 2021-05-14 2022-11-16 Ustav organicke chemie a biochemie AV CR, v.v.i. Antikörper mit bindung an rbd des spike-proteins von sars-cov-2 und verfahren zur quantifizierung von schützenden antikörpern gegen sars-cov-2
WO2023148641A1 (en) * 2022-02-02 2023-08-10 Translational Health Science And Technology Institute Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof

Also Published As

Publication number Publication date
NZ560328A (en) 2010-05-28
JP2008529504A (ja) 2008-08-07
CA2595780A1 (en) 2006-08-17
EP1855719A2 (de) 2007-11-21
WO2006086561A3 (en) 2009-04-23
ES2384497T3 (es) 2012-07-05
AU2006213775A1 (en) 2006-08-17
AU2006213775C1 (en) 2011-11-03
BRPI0606148A2 (pt) 2009-06-02
EP1855719A4 (de) 2009-11-04
WO2006086561A2 (en) 2006-08-17
AU2006213775B2 (en) 2010-11-11
MX2007009512A (es) 2008-02-21

Similar Documents

Publication Publication Date Title
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
UA109633C2 (uk) Антитіло людини проти тканинного фактора
NO20043245L (no) Bindingsproteiner som biosensorer
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
ATE473760T1 (de) Monoklonale antikörper gegen den hepatozyten- wachstumsfaktor
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
EA201000424A1 (ru) Антитела к il-23
BR0314038A (pt) Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
MX340547B (es) Equipos de prueba de diagnostico.
ATE497774T1 (de) Screening kombinatorischer proteinbibliotheken mittels periplasmatischer expression
UA105760C2 (uk) Антитіло проти bst2
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
ATE412179T1 (de) Nachweis von arzneistoffen der methamphetamingruppe
WO2010031749A9 (en) Compositions and methods for detecting tlr3
WO2009070507A3 (en) Anaplasma phagocytophilum (aph) antigens and antibodies specific for anaplasma
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства